film dissertation help homework writing services which essay writing service is reliable computer assignment creative writing magazines uk how to write an admission essay english mba essay service review how to do your homework last minute coursework writing help how to brainstorm for an essay

Catalogue of Services

What do LS RIs offer the life science community?

 

The 13 European Life Science Research Infrastructures (LS RIs) have the mission to support cutting-edge science by offering access to their resources and services to European scientists from academia and industry.

Resources and services can simply be consultation, access to experts, but also access to data and biological samples, use of data analysis tools, access to facilities (e.g. highly specialised microscopes) plus support from technicians and much more.

Some of these services are even free to use for institutions location in the RI's member states. 

 

The Catalogue of Services, which has been developed within the CORBEL project, is the first tool to list the main services of all LS RIs at a glance and it aims to facilitate the utilisation of RI services by researchers from all over the world. The Catalogue of Services as displayed below aims to provide you a basic overview on existing services within distinct thematic fields.

 

You can either use the Catalogue of Services to identify a single RI to help you with your work or you can create a service pipeline, i.e. using several RIs simultaneously.

What’s your need?

Please select…

EU-OPENSCREEN

Contact person(s): Project Manager: Dr. Tanja Miletic

EU-OPENSCREEN integrates high-capacity screening platforms throughout Europe, which jointly use a rationally selected compound collection, comprising up to 140.000 commercial and proprietary compounds collected from European chemists. EU-OPENSCREEN offers to researchers from academic institutions, SMEs and industrial organisations open access to its shared resources.

EU-OPENSCREEN will collaboratively develop novel molecular tool compounds with external users from various disciplines of the life sciences.

Services provided

Services provided by EU-OPENSCREEN include

  • high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits
  • access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)
  • assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors (e.g. signal to background and the Z’ factor) 
  • chemical optimization and profiling of preliminary ‘hits’
  • bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.
  • provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.
  • training and education activities

Costs

A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k €, strongly depending on the number of screened substances and the maturity/ complexity of the assay.
A compound replenishment fee structure applies to all projects using the EU-OPENSCREEN compound collection and users from countries which are members of the EU-OPENSCREEN ERIC will receive a discount on this cost.
For further information please contact us.

Access modes

Users are requested to submit project proposal to the EU-OPENSCREEN office. Depending on the project requirements, the RI can be assessed remotely or on-site.

Why work with us

The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through grant application processes and beyond for funding involving screening projects.

Countries involved

CZ, FI, DE, LV, NO, PO, ES, DK

Services contact

Contact person(s): Project Manager: Dr. Tanja Miletic

About

Chemical Biology is a new interdisciplinary research field which studies the effects of chemical compounds on biological systems. The primary objective of EU-OPENSCREEN is to offer access to a distributed Chemical Biology research infrastructure which meets the needs of scientists seeking a better understanding on how fundamental molecular processes act to govern biological function at the organismal, tissue, cellular and pathway levels by applying small chemical compounds.

Using a well-founded collaborative working model, infrastructure users and EU-OPENSCREEN teams will identify and develop novel small chemical compounds which elicit specific biological responses on organisms, cells or cellular components. These bioactive compounds are identified by means of screening large collections of >100,000 molecules, in an automated process, using robotics-based high-throughput screening platforms, and optimised by medicinal chemistry means.

The majority of scientists in Europe, however, do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; constructing a jointly used compound collection; and operating an open-access bioactivity database which will be accessible on a global basis.

The chemical compounds which will be developed in the framework of EU-OPENSCREEN have a number of key advantages and allow interrogation of complex biological processes that cannot be properly studied with traditional genetic approaches. They drive innovation as they help validate biological targets as ‘druggable’ (i.e. be modulated by chemical compounds) which makes them highly attractive starting points for further optimisation into marketable medicines or crop-protective agents by pharmaceutical, AgriScience and biotechnology companies.  

Access to the EU-OPENSCREEN expertise and resources is available to all researchers worldwide. EU-OPENSCREEN will represent a globally relevant resource and will attract users from a variety of scientific disciplines and geographical regions. The key users can be divided into three major user groups:

  1. Assay providing users who will access the screening infrastructure: Researchers with a suitable, robust and screening compatible assay, interested in developing specific chemical compounds (i.e. inhibitor or activator) for their biological mechanism or pathway-of-interest to answer a biological question. In the first step, these assays are screened against the EU-OPENSCREEN ERIC compound collection; in the second step, the identified active compounds (‘hits’) are chemically optimised and translated into valuable tool compounds, which are made available to the broader scientific community.
  2. Compound providing users who will donate compounds: Chemists who donate their compounds can use the EU-OPENSCREEN services to expose their compounds to a large number of screens, and thereby a wide range of biological targets. The unique value proposition for chemists is that the biological activities of their compounds will be described in-depth and that their compounds may be identified as active 'hit' compounds, thereby triggering new collaborations between chemistry and biology communities.
  3. Database users who will access the EU-OPENSCREEN database: The open-access EU-OPENSCREEN database will serve as the publicly accessible database and collaborative data sharing environment for all EU-OPENSCREEN generated data. It is designed to support the requirements of both academia (encouraging exchange of knowledge) and industry (allowing suitable protection of IP).

General contact

Website: www.eu-openscreen.eu

Contact person(s): office(at)eu-openscreen.eu

Please note: Most of the RIs are constantly developing their portfolio of services, so if you do not find the service/tool you are looking for, do not hesitate to contact the RI and ask for it!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 654248.